Carolina Infusion, LLC
Has Carolina Infusion, LLC received an FDA warning letter about GLP-1 drugs?
No FDA warning letter to Carolina Infusion, LLC naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 11 drug recall reports for it naming semaglutide and tirzepatide, the latest initiated Sep 10, 2026.
FDA records in this index name Carolina Infusion, LLC from Aug 26, 2022 to Sep 10, 2026.
- Names in FDA records
- Carolina Infusion, LLC; Carolina Infusion
- Type named in FDA records
- Not stated
- FDA warning letters
- 0
- Drug recall reports
- 11
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Sep 10, 2026
FDA warning letters
FDA records print this firm both as “Carolina Infusion, LLC” and “Carolina Infusion”. They are shown together because one form has no legal ending and no other firm with that name appears in this index’s data; each row below gives the name as FDA printed it.
No FDA warning letters in this index.
Drug recalls
| Record | ||||||
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Carolina Infusion, LLC | SEMAGLUTIDE/CYANOCOBALAMIN 9/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0026-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | SEMAGLUTIDE/CYANOCOBALAMIN 3/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0019-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | SEMAGLUTIDE 3 MG/ML INJECTABLE, 8 x 0.1 mL syringes, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936 | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0018-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 26/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0027-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 85/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0030-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 64/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0028-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 76/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0029-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE 26 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infus... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0017-2027 |
| Aug 26, 2022 | Carolina Infusion | Semaglutide/Cyanocobalamin 24/2 MG/ML Injectable, 0.4 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936. | Lack of Assurance of Sterility | Class II | Completed | D-1521-2022 |
| Aug 26, 2022 | Carolina Infusion | Semaglutide/Cyanocobalamin 5/2 MG/ML Injectable, 0.2 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936. | Lack of Assurance of Sterility | Class II | Completed | D-1519-2022 |
| Aug 26, 2022 | Carolina Infusion | Semaglutide/Cyanocobalamin 10/2 MG/ML Injectable, 0.4 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936. | Lack of Assurance of Sterility | Class II | Completed | D-1520-2022 |
FDA compounding inspections and actions
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.
Carolina Infusion, Ridgeland, SC (503A)
4 listed actions, including 3 Form 483s and 1 warning letter (2022 to 2026).
| Document | |||
|---|---|---|---|
| Aug 18, 2026 | Form 483 | 483 Issued 08/18/2026 | fda.gov |
| Jan 24, 2025 | Form 483 | 483 Issued 01/24/2025 | FDA copy (archived) |
| May 22, 2023 | Warning letter | Warning Letter (05/22/2023) | FDA copy (archived) |
| Aug 12, 2022 | Form 483 | 483 Issued 08/12/2022 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Carolina Infusion, Ridgeland, SC.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- openFDA drug recall enforcement reports
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.